TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03570554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER
Description: 3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER
Description: 3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER
Description: 3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER
Description: 3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over-encapsulation capsule, 4 days, oral (Treatment D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over-encapsulation capsule, 4 days, oral (Treatment D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over-encapsulation capsule, 4 days, oral (Treatment D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Over-encapsulation capsule, 4 days, oral (Treatment D)
Study: NCT04355806

Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors
Description: Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.

Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors
Description: Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.

Intervention type: BIOLOGICAL
Intervention: Inactivated trivalent influenza vaccine
Description: Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.

Intervention type: BIOLOGICAL
Intervention: Inactivated trivalent influenza vaccine
Description: Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
Study: NCT01712334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dornase alfa [Pulmozyme®]
Description: Inhaled once daily by Pari eRapid nebulizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa [Pulmozyme®]
Description: Inhaled once daily by Pari LC Plus jet nebulizer.
Study: NCT01297166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27989 ointment
Description: once daily application, 3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus LEO 27989 ointment
Description: once daily application, 3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Description: once daily application, 3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ointment
Description: once daily application, 3weeks
Study: NCT01801280

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate sodium
Description: Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate sodium
Description: Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole
Description: Daily dose: 40mg. Application together with CellCept® or Myfortic® .

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole
Description: Daily dose: 40mg. Application together with CellCept® or Myfortic® .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
Study: NCT02720900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B-GOS
Description: 1.8 g/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 1.8 g/day for 6 weeks
Study: NCT01983072

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding
Description: Breastfeeding
Study: NCT01254851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: goal-augmented post-operative care
Description: Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
Study: NCT03530813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ebook Asthma First Aid in School Training
Description: Technology assisted, self-directed learning eBook resource

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-To-Face Asthma First Aid in Schools Training
Description: School Asthma First Aid Management Program 3 Hour Face to Face Training
Study: NCT04991363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bleaching
Description: Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
Study: NCT04094272

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic doppler-echocardiography (TTE)
Description: Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
Study: NCT00359736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sildenafil
Description: Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
Study: NCT02255552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eteplirsen
Description: Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Study: NCT02847182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cord Blood Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04367493

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 25 g of chocolate by day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 25 g of chocolate by day for 4 weeks
Study: NCT02603562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study: NCT00785434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Dose ranging up to 50mg
Study: NCT02059434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 1 (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS190792 Dose 2 (Part 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol 150 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02292186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revusiran (ALN-TTRSC)
Study: NCT02691429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acai dye 10%
Description: dye to be used during chromovitrectomy in humans

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acai dye 10%
Description: dye to be used during chromovitrectomy in humans
Study: NCT01623037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the each flank with a defined cooling rate and duration.
Study: NCT04039178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BQ
Description: The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham BQ device
Study: NCT00146900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: 12 weekly 1.5 hours weekly session of cognitive therapy without exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
Study: NCT01838434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idelalisib
Description: given PO
Study: NCT02203851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study: NCT03787303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Description: Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
Study: NCT03085992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus Bevacizumab
Description: * BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus Bevacizumab
Description: * FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~* BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles).
Study: NCT03276468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes\>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
Study: NCT03740321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolization with tri-acryl gelatin (Embosphere) particles
Description: Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolization with tri-acryl gelatin (Embosphere) particles
Description: Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
Study: NCT04151485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind/Body Program for Fertility (Domar et al., 2011)
Description: see Arm Description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fertility Support Program
Description: see Arm Description
Study: NCT01459718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20-40 mg/kg/day orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: 40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week
Study: NCT00292110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 100 mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 100 mg/day orally

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Incentives given for cocaine abstinence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Incentives given for cocaine abstinence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone dose
Description: flexible methadone dosing to 190 mg/day daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone dose
Description: flexible methadone dosing to 190 mg/day daily orally
Study: NCT03868293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound
Description: Pulsed low intensity focused ultrasound
Study: NCT03292146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 MG [Prolia]
Description: Denosumab 60mg injection at baseline and 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo Injection at baseline and 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate 70Mg Tab
Description: Alendronate 70mg PO weekly starting at Month 12 through 24 months.
Study: NCT00292110

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management/Noncontingent Incentives
Description: Incentives given independent of drug use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management/Noncontingent Incentives
Description: Incentives given independent of drug use
Study: NCT02946814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: essential oils

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: essential oils without mouthwash

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sterile water
Study: NCT00622336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: Oral 25mg daily on Days 1-21 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
Study: NCT03521817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: The ethanol group will consume a 30% energy restriction diet that will also include \~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Alcohol
Description: This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
Study: NCT02847923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of alternative communication application
Description: At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Familiarization with the software interface
Description: At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test of the software
Description: Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Answer the questionnaire
Description: After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
Study: NCT02833935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants.
Study: NCT00423189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Description: as needed, one intravitreal injection of 0.50mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Description: as needed, one intravitreal injection of 0.50mg ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: as needed, one intravitreal injection of 0.50mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg ranibizumab
Description: as needed, one intravitreal injection of 0.50mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg ranibizumab
Description: as needed, one intravitreal injection of 0.50mg ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg ranibizumab
Description: as needed, one intravitreal injection of 0.50mg ranibizumab
Study: NCT04258215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Routine positive pressure airway management.
Description: The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
Study: NCT05471570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS stimulation
Description: The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS stimulation
Description: The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.
Study: NCT02479971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin irrigation
Description: An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline irrigation
Description: An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
Study: NCT02250066

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid